Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. 
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?

View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold

Ask for high quality link by putting your email below


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

2 Comments

SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm

[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]

Feedback from TERMIS congress in Nantes! by HCS Pharma | HCS Pharma · September 16, 2019 at 5:33 pm

[…] research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product range, about iPSC-derived hepatocytes in BIOMIMESYS® Liver, and about BIOMIMESYS® for organ-on-chip […]

Leave a Reply